The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000
This development signals a cleanup of Anlon’s borrowing profile and closure of legacy debt facilities
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Subscribe To Our Newsletter & Stay Updated
